Case... August 2006
GENMAB: GLOBAL HQ AND R&D CENTRE
Why Denmark? "Part of the reason for Genmab’s success is the valuable resources we have access to in Denmark. We have been able to find very highly skilled and experienced professionals who enable us to carry our programs forward in a streamlined fashion. We have also found Denmark to be a prime location in that it provides easy access to clinical sites and capital in other Scandinavian and European countries. Making our start as a Danish company has given us a significant advantage in the competitive field of biotechnology." Lisa N. Drakeman, Ph.D., CEO, Genmab A/S
Genmab is a biotechnology company founded in 1999. It currently employs approx. 200 people at its offices in Copenhagen, Utrecht and Princeton. The company is publicly traded on the Copenhagen Stock Exchange with Princeton based GenPharm International, Inc. as the largest stockholderwith 25% of the shares.
CASE: GENMAB GLOBAL HQ AND R&D CENTRE
The reasons for choosing Denmark: • Unique combination of cost and quality • Access to an excellent research community on all levels from basic research through the clinical phases • Very strong clinical trials environment with easy access to qualified medical professionals • A health care system with ample capacity to meet the clinical needs of the biotech industry • Denmark’s competitiveness as one of the top two cancer centres of Europe and Medicon Valley’s status in the absolute world elite in research in inflammatory conditions • The supportiveness of the local investment community in terms of assembling the right working team and professional network for Genmab
I nt .
sa le
s
R e s e a r ch
P r od u
c ti o
n
ing t test rke Ma
Biz Solutions
De
pm
n
en
t
si g
App
l ica ti o n
De
ve
lo
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products – therapeutical areas where Denmark and Medicon Valley are strongly positioned. In addition, Genmab is involved in multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen, and GlaxoSmithKline.
Denmark at a glance • World’s Best Place to conduct business in a five-year perspective (Economist Intelligence Unit 2007-2011) • No. 3 on the global competitiveness overall scoreboard (World Economic Forum 2007) • No. 3 in the world on the basis of availability of venture capital for business development(IMD 2007) • No. 3 in the world on the basis of flexible labor regulations (IMD 2007) • No. 1 in the world for corporate values (IMD 2007) • Highest worker motivation in the world (IMD 2007)
Whether your company considers to relocate, consolidate, set up new production facilities, is on the lookout for new innovation partners or other strategic business solutions in Europe, Invest in Denmark is a good place to begin. We provide customised information and services free of charge and in full confidentiality.
Invest in Denmark 2, Asiatisk Plads DK-1448 Copenhagen K Tel. +45 33 92 11 16 Fax +45 33 92 07 17